Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)J. Clin. Oncol 2022 Apr 20;[EPub Ahead of Print], MB Atkins, OA Jegede, NB Haas, DF McDermott, MA Bilen, M Stein, JA Sosman, R Alter, ER Plimack, M Ornstein, M Hurwitz, DJ Peace, S Signoretti, T Denize, A Cimadamore, CJ Wu, D Braun, D Einstein, PJ Catalano, H Hammers
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.